Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 5, 2023

Exploration on Short Term Efficacy and Safety of PD-1 Immunotherapy Combined with Neoadjuvant Chemotherapy in the Treatment of Non-small Cell Lung Cancer

Download as PDF

DOI: 10.23977/medsc.2023.040509 | Downloads: 11 | Views: 377

Author(s)

Ning Hui 1, Lei Guangyan 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, 710065, China

Corresponding Author

Lei Guangyan

ABSTRACT

The purpose of this study is to explore the short-term efficacy and safety of PD-1/PD-L1 immunotherapy combined with neoadjuvant chemotherapy in the treatment of resectable non-small cell lung cancer. Collect clinical data of 89 non-small cell lung cancer patients who underwent PD-1/PD-L1 immunotherapy combined with neoadjuvant chemotherapy from January 2020 to December 2022 in the first and second extrathoracic wards of our hospital, aged 50.0 to 82.0 (68.0 ± 8.5) years old. Retrospective analysis of the imaging data and pathological changes of patients before and after PD-1/PD-L1 immunotherapy combined with neoadjuvant chemotherapy treatment, recording the adverse reactions that occurred during the treatment process, with objective response rate, main pathological response rate, and pathological complete response rate as the main observation indicators. The results showed that after PD-1 immunotherapy combined with neoadjuvant therapy, all patients successfully underwent thoracoscopic radical resection of lung cancer. According to the RECIST 1.1 standard evaluation analysis, 16 patients achieved complete remission and 36 patients achieved partial remission, with an objective remission rate of 58.43%; There were 17 PCR patients and 61 MPR patients, with a main pathological response rate of 87.64%. The main adverse reactions of the patients were Hypoalbuminemia, decreased appetite and nausea. Most patients were mild, and no drug intervention was needed; There were no deaths or tumor metastasis within one month after surgery. Therefore, the combination of PD-1/PD-L1 immunotherapy and neoadjuvant chemotherapy for resectable non-small cell lung cancer is safe and can effectively improve postoperative symptoms and promote patient recovery.

KEYWORDS

PD-1 immunity; Neoadjuvant chemotherapy; Non-small cell lung cancer

CITE THIS PAPER

Ning Hui, Lei Guangyan, Exploration on Short Term Efficacy and Safety of PD-1 Immunotherapy Combined with Neoadjuvant Chemotherapy in the Treatment of Non-small Cell Lung Cancer. MEDS Clinical Medicine (2023) Vol. 4: 60-67. DOI: http://dx.doi.org/10.23977/medsc.2023.040509.

REFERENCES

[1] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021, 71(3):209-49. 
[2] Hou Wenxuan. Study on the effect of PD-1 immunocheckpoint inhibitor combined with chemotherapy in preoperative neoadjuvant treatment of stage IIIA/IIIB lung squamous cell carcinoma [D]. Qinghai University, 2020, 6. 
[3] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-32. 
[4] Travis W D, Brambilla E, Nicholson A G, et al. The 2015 WorldHealth Organization Classification of Lung Tumors [J]. Journal of Thoracic Oncology, 2015, 10(9): 1243-60
[5] Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J]. Journal of Thoracic Oncology, 2016, 11(1): 39-51. 
[6] Morgensztern D, Ng S H, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey [J]. J Thorac Oncol, 2010, 5(1): 29-33. 
[7] Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer [J]. Lancet, 2016, 387(10026): 1354-1356. 
[8] Yi Xing, Zhao Heng, Liu Bohao, et al. Short term efficacy and safety of Pembrolizumab combined with neoadjuvant chemotherapy in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Cardiothoracic Surgery, 2023, 30 (3): 369-374. 
[9] Artal Cortés Á, Calera Urquizu L, Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art [J]. Translational lung cancer research, 2015, 4(2): 191-7
[10] Yamaguchi H, Hsu JM, Yang WH, et al. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics[J]. Nat Rev Clin Oncol, 2022, 19(5):287-305. 
[11] Lesch S, Gill S. The promise and perils of immunotherapy [J]. Blood Adv, 2021, 5(18):3709-3725. 
[12] Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8):525-543. 
[13] Zhang L, Zhao Y, Tu Q, et al. The roles of programmed cell death ligand-1/ programmed cell death-1(PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy [J]. Curr Med Chem, 2021, 28(5): 893-909. 
[14] Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: Non-small cell lung cancer, version 2. 2021[J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266
[15] Liu Yutao, Gao Yushun, Mao Yousheng, et al. Efficacy and safety of Programmed cell death protein 1 monoclonal antibody combined with chemotherapy in preoperative neoadjuvant treatment of stage II and III non-small cell lung cancer [J]. Chinese Journal of Cancer, 2020, 42 (6): 480-485. 
[16] Bai Yue, Sun Daqiang, Zhang Xun, etc Randomized controlled study of PD-1 inhibitor combined with chemotherapy in preoperative neoadjuvant treatment of stage III non-small cell lung cancer [J]. Chinese Journal of Thoracic Cardiovascular Surgery, 2021, 28 (8): 963-971. 
[17] Zhao Z, Gao Y, Xue Q, et al. Safety and efficacy of neoadjuvant immune checkpoint inhibitor therapy in patients with resectable non-small-cell lung cancer: A systematic review [J]. Target Oncol, 2021, 16(4): 425-434. 
[18] Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination[J]. Nat Rev Clin Oncol, 2016, 13(8): 473-486. 
[19] Cheng Mengzhi. Comparative study on the operation and therapeutic effect of PD-1 immune combined chemotherapy neoadjuvant and traditional neoadjuvant chemotherapy in the treatment of NSCLC [D]. Dalian Medical University, 2022, 2.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4716
Visits: 205524

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.